Pulmonology & Thoracic Medicine

Idiopathic Pulmonary Fibrosis

Antifibrotic therapy (nintedanib, pirfenidone) and lung transplant evaluation.

Treatment Options

Recommended Centers

$2,500

Starting From

7-21 days

Typical Wait

Treatment Plans for Idiopathic Pulmonary Fibrosis

Compare evidence-based options at top Chinese hospitals — transparent pricing, typical wait, and recovery time.

Flagship Plan

Pirfenidone Antifibrotic Therapy (Annual)

Daily oral antifibrotic with quarterly LFT and PFT monitoring.

Wait Time

5-7 days

Hospital Stay

Annual maintenance

Recovery

Outpatient

Estimated Price

Approx. $3,500/year

View Detailed Introduction — Procedure, Price Comparison & More

Price Comparison: China vs. USA

🇨🇳 China

$2,500

🇺🇸 USA

$13,750+

Save up to $11,250 per treatment

Procedure Steps

Pre-treatment: HRCT chest + PFTs (FVC, DLCO) + 6MWT + ILD multidisciplinary review

Baseline LFTs + photosensitivity assessment

Pirfenidone titration: Week 1: 267mg TID, Week 2: 534mg TID, Week 3+: 801mg TID

Take with food to reduce GI side effects

Photosensitivity protection: strict sunscreen + sun avoidance

Monthly LFT monitoring for first 6 months

Every 3-6 months: FVC, DLCO, 6MWT

Continue indefinitely if tolerated and effective

What is Pirfenidone for IPF?

An oral antifibrotic drug that slows the progression of idiopathic pulmonary fibrosis by inhibiting multiple fibrotic pathways. Combined with comprehensive ILD care, it extends life expectancy and preserves lung function.

Why China?

Cost (annual): $2,500-$5,500 (domestic) vs. $95,000-$120,000 in the US
Domestic production: Chinese-made pirfenidone + nintedanib at fraction of Western prices
ILD expertise: China-Japan Friendship Hospital is Asia's leading ILD center
Comprehensive management: Integrated pulmonary rehab + O2 therapy + transplant evaluation

Who is a candidate?

Confirmed IPF (UIP pattern on HRCT or biopsy)
FVC 50-80% predicted (disease-modifying window)
ECOG 0-2
Unexplained progressive fibrosing ILD (now also indicated)

Outcomes

FVC decline reduction: ~50%. Disease progression slowing: significant. Median survival extension: 1-2 years vs untreated. Common adverse effects: GI upset (30%), photosensitivity (20%) — usually manageable.

Book Free Consultation WhatsApp

Prices are indicative ranges in USD based on partner hospital published rates. Final quote depends on your medical records and selected hospital — request a free personalized estimate.